[{"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-001", "question": "A 5-month-old infant presents with exaggerated startle response to noise, progressive motor regression, and bilateral macular cherry-red spots. Serum hexosaminidase A and B levels are within normal limits. Genetic sequencing reveals a mutation in the GM2A gene. Which of the following is the correct diagnosis?", "options": ["Tay-Sachs disease", "Sandhoff disease", "GM2 activator deficiency", "Sialidosis type I", "Niemann-Pick disease type A"], "answer": "C", "answer_index": 2, "explanation": "The clinical phenotype mimics Tay-Sachs (Hex A deficiency) and Sandhoff (Hex A and B deficiency) diseases, including the cherry-red spot and startle response. However, normal enzyme levels with a mutation in GM2A indicate the AB variant of GM2 gangliosidosis, caused by a deficiency in the GM2 activator protein required for the interaction between the lipid substrate and the enzyme.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include exaggerated startle response, progressive motor regression, bilateral macular cherry-red spots, normal serum hexosaminidase A and B levels, and GM2A gene mutation. These findings point to GM2 gangliosidosis AB variant (GM2 activator deficiency), as the mutation affects the activator protein needed for hexosaminidase function, despite normal enzyme levels, mimicking Tay-Sachs/Sandhoff clinically but distinguished by genetics and enzyme assays. Main logical issue(s): none; the stem provides sufficient discriminating details (normal enzymes + specific mutation) to identify C as uniquely best, with alternatives eliminable (A/B require enzyme deficiencies; D involves sialidase deficiency without GM2A link; E is sphingomyelinase-related). Main medical accuracy issue(s): none; aligns with consensus on GM2 gangliosidosis variants, including AB type due to GM2A mutations causing ganglioside accumulation, per standard pediatric neurology guidelines (e.g., consistent with USMLE-level knowledge on lysosomal storage disorders). Minimal fix: none needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include exaggerated startle response, progressive motor regression, bilateral macular cherry-red spots, normal serum hexosaminidase A and B levels, and GM2A gene mutation. These findings point to GM2 gangliosidosis AB variant (GM2 activator deficiency), as the mutation affects the activator protein needed for hexosaminidase function, despite normal enzyme levels, mimicking Tay-Sachs/Sandhoff clinically but distinguished by genetics and enzyme assays. Main logical issue(s): none; the stem provides sufficient discriminating details (normal enzymes + specific mutation) to identify C as uniquely best, with alternatives eliminable (A/B require enzyme deficiencies; D involves sialidase deficiency without GM2A link; E is sphingomyelinase-related). Main medical accuracy issue(s): none; aligns with consensus on GM2 gangliosidosis variants, including AB type due to GM2A mutations causing ganglioside accumulation, per standard pediatric neurology guidelines (e.g., consistent with USMLE-level knowledge on lysosomal storage disorders). Minimal fix: none needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-002", "question": "A 3-day-old neonate presents with intractable seizures refractory to phenobarbital, phenytoin, and levetiracetam. The EEG shows a burst-suppression pattern. Administration of intravenous pyridoxine yields no improvement. Subsequent administration of pyridoxal-5'-phosphate results in immediate cessation of clinical and electrographic seizure activity. Which enzyme is deficient?", "options": ["Antiquitin (ALDH7A1)", "Pyridox(am)ine 5'-phosphate oxidase (PNPO)", "Glutamic acid decarboxylase (GAD)", "GABA transaminase", "Succinic semialdehyde dehydrogenase"], "answer": "B", "answer_index": 1, "explanation": "Pyridoxine-dependent epilepsy (ALDH7A1 deficiency) responds to pyridoxine. However, patients with PNPO deficiency cannot convert pyridoxine to the active form, pyridoxal-5'-phosphate (PLP). They present with similar intractable seizures but require PLP specifically for treatment.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include neonatal intractable seizures refractory to phenobarbital, phenytoin, and levetiracetam; burst-suppression EEG; no response to IV pyridoxine but immediate cessation with pyridoxal-5'-phosphate (PLP). These discriminate PNPO deficiency, as it impairs conversion of pyridoxine to active PLP, requiring direct PLP administration. The clinical problem asks for the deficient enzyme in vitamin B6-dependent epilepsy variant unresponsive to pyridoxine but responsive to PLP. Key findings: early-onset refractory seizures, specific EEG pattern, differential treatment response. Most likely diagnosis: PNPO deficiency. Keyed answer B fits perfectly, assuming standard metabolic pathways without unstated complications. Alternatives: A (ALDH7A1) incorrect as it responds to pyridoxine; C (GAD) worse as it's PLP-dependent but not deficient here and lacks specific seizure response; D and E relate to GABA metabolism but not to B6/PLP specificity. Main logical issues: none; stem allows unique discrimination. Main medical accuracy issues: none; aligns with current guidelines on pyridoxine-dependent epilepsies (e.g., ALDH7A1 vs. PNPO distinctions in neonatal seizures). Minimal fix: none required, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include neonatal intractable seizures refractory to phenobarbital, phenytoin, and levetiracetam; burst-suppression EEG; no response to IV pyridoxine but immediate cessation with pyridoxal-5'-phosphate (PLP). These discriminate PNPO deficiency, as it impairs conversion of pyridoxine to active PLP, requiring direct PLP administration. The clinical problem asks for the deficient enzyme in vitamin B6-dependent epilepsy variant unresponsive to pyridoxine but responsive to PLP. Key findings: early-onset refractory seizures, specific EEG pattern, differential treatment response. Most likely diagnosis: PNPO deficiency. Keyed answer B fits perfectly, assuming standard metabolic pathways without unstated complications. Alternatives: A (ALDH7A1) incorrect as it responds to pyridoxine; C (GAD) worse as it's PLP-dependent but not deficient here and lacks specific seizure response; D and E relate to GABA metabolism but not to B6/PLP specificity. Main logical issues: none; stem allows unique discrimination. Main medical accuracy issues: none; aligns with current guidelines on pyridoxine-dependent epilepsies (e.g., ALDH7A1 vs. PNPO distinctions in neonatal seizures). Minimal fix: none required, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-003", "question": "A 35-year-old male with Myotonic Dystrophy Type 1 presents for emergency appendectomy. Following induction with propofol and succinylcholine, the patient develops generalized muscle rigidity, making ventilation impossible. The heart rate is 110 bpm and temperature is 37.2°C. Which of the following best explains the pathophysiology of this reaction?", "options": ["Uncontrolled calcium release from the sarcoplasmic reticulum via the ryanodine receptor", "Prolonged depolarization of the motor endplate causing sodium channel inactivation failure", "Exaggerated contracture due to sodium channel hyperexcitability distal to the neuromuscular junction", "Denervation hypersensitivity leading to massive potassium efflux", "Deficiency of pseudocholinesterase leading to prolonged blockade"], "answer": "C", "answer_index": 2, "explanation": "This is a succinylcholine-induced myotonic contracture, not Malignant Hyperthermia (MH). In myotonic dystrophy, the muscle membrane is hyperexcitable. Succinylcholine causes a sustained, generalized contracture that acts as a 'chemical splint,' preventing ventilation. Unlike MH, it is not mediated by the RYR1 receptor and does not respond to dantrolene.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 35-year-old male with Myotonic Dystrophy Type 1 (DM1) undergoes induction with propofol and succinylcholine, developing generalized muscle rigidity preventing ventilation; HR 110 bpm, temperature 37.2°C (no hyperthermia). These clues point to succinylcholine-induced myotonic contracture due to DM1-associated muscle membrane hyperexcitability, not malignant hyperthermia (MH) or other complications.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting C as the unique best answer based on pathophysiology of exaggerated contracture from sodium channel hyperexcitability distal to the neuromuscular junction.\\nMain medical accuracy issue(s), if any: None; aligns with current understanding that in DM1 (DMPK gene expansion affecting chloride channels), succinylcholine triggers sustained myotonia via membrane instability, distinct from MH (RYR1-mediated calcium release). Rationale correctly notes lack of dantrolene response and absence of MH features.\\nMinimal fix: No edit needed; item is already unambiguous and accurate, though adding 'no hyperkalemia or metabolic acidosis' could further emphasize exclusion of option D if desired.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 35-year-old male with Myotonic Dystrophy Type 1 (DM1) undergoes induction with propofol and succinylcholine, developing generalized muscle rigidity preventing ventilation; HR 110 bpm, temperature 37.2°C (no hyperthermia). These clues point to succinylcholine-induced myotonic contracture due to DM1-associated muscle membrane hyperexcitability, not malignant hyperthermia (MH) or other complications.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting C as the unique best answer based on pathophysiology of exaggerated contracture from sodium channel hyperexcitability distal to the neuromuscular junction.\nMain medical accuracy issue(s), if any: None; aligns with current understanding that in DM1 (DMPK gene expansion affecting chloride channels), succinylcholine triggers sustained myotonia via membrane instability, distinct from MH (RYR1-mediated calcium release). Rationale correctly notes lack of dantrolene response and absence of MH features.\nMinimal fix: No edit needed; item is already unambiguous and accurate, though adding 'no hyperkalemia or metabolic acidosis' could further emphasize exclusion of option D if desired.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-004", "question": "A patient with a known diagnosis of Erythropoietic Protoporphyria (EPP) is undergoing a prolonged laparotomy. Which of the following intraoperative interventions is most critical to prevent cutaneous injury in this specific patient?", "options": ["Avoidance of nitrous oxide", "Placement of yellow filters over the operating lights", "Strict avoidance of volatile anesthetics", "Administration of high-dose corticosteroids", "Maintenance of normothermia to prevent precipitation"], "answer": "B", "answer_index": 1, "explanation": "Patients with EPP accumulate protoporphyrin IX, which is phototoxic upon exposure to light in the violet/blue spectrum (Soret band, ~400-410 nm). Standard operating lights emit significant energy in this range, causing severe phototoxic skin burns and potential intestinal injury during laparotomy. Yellow filters block this specific wavelength.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Patient with known EPP undergoing prolonged laparotomy; question focuses on preventing cutaneous injury, implying need to address phototoxicity from operating lights due to protoporphyrin IX accumulation. Positive clues: EPP diagnosis, surgical exposure. Negative clues: No mention of other porphyria types or triggers like drugs/ temperature affecting acute attacks.\\nMain logical issue(s), if any: None; stem provides sufficient detail to discriminate B as uniquely best, with alternatives unrelated or less critical to photoprotection.\\nMain medical accuracy issue(s), if any: None; aligns with standard knowledge that EPP causes photosensitivity to ~400-410 nm light, and yellow filters are recommended to block this during surgery, preventing burns. Rationale correctly references Soret band and phototoxicity, consistent with guidelines (e.g., from porphyria experts).\\nMinimal fix: No fix needed; item is already unambiguous and accurate. If enhancing, add 'prolonged exposure to operating room lights' to stem for emphasis, but not required.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Patient with known EPP undergoing prolonged laparotomy; question focuses on preventing cutaneous injury, implying need to address phototoxicity from operating lights due to protoporphyrin IX accumulation. Positive clues: EPP diagnosis, surgical exposure. Negative clues: No mention of other porphyria types or triggers like drugs/ temperature affecting acute attacks.\nMain logical issue(s), if any: None; stem provides sufficient detail to discriminate B as uniquely best, with alternatives unrelated or less critical to photoprotection.\nMain medical accuracy issue(s), if any: None; aligns with standard knowledge that EPP causes photosensitivity to ~400-410 nm light, and yellow filters are recommended to block this during surgery, preventing burns. Rationale correctly references Soret band and phototoxicity, consistent with guidelines (e.g., from porphyria experts).\nMinimal fix: No fix needed; item is already unambiguous and accurate. If enhancing, add 'prolonged exposure to operating room lights' to stem for emphasis, but not required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-005", "question": "A 45-year-old female with breast cancer is being treated with tamoxifen. She develops major depressive disorder. Which of the following antidepressants is contraindicated due to a pharmacokinetic interaction that would reduce the oncologic efficacy of her breast cancer treatment?", "options": ["Venlafaxine", "Escitalopram", "Paroxetine", "Desvenlafaxine", "Mirtazapine"], "answer": "C", "answer_index": 2, "explanation": "Tamoxifen is a prodrug that requires conversion to its active metabolite, endoxifen, primarily via the CYP2D6 enzyme. Paroxetine (and fluoxetine) is a potent CYP2D6 inhibitor, which can significantly lower endoxifen levels and potentially increase the risk of breast cancer recurrence. Venlafaxine and escitalopram have minimal effect on CYP2D6.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 45-year-old female with breast cancer on tamoxifen develops major depressive disorder; question asks for antidepressant contraindicated due to pharmacokinetic interaction reducing oncologic efficacy. These clues point to avoiding strong CYP2D6 inhibitors, as tamoxifen requires CYP2D6 for conversion to active endoxifen. Main logical issue(s): None; stem provides sufficient details for discrimination, with options allowing clear selection of paroxetine as the only strong inhibitor among choices. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., NCCN, ASCO) warning against strong CYP2D6 inhibitors like paroxetine with tamoxifen due to reduced endoxifen levels and potential recurrence risk. Venlafaxine, escitalopram, desvenlafaxine, and mirtazapine have minimal to no CYP2D6 inhibition. The item's logic is sound, reflecting standard pharmacotherapy knowledge without inaccuracies or outdated info. Minimal fix: None needed, as item is already unambiguous and accurate. Best-answer defensibility: Clinical problem restated - Identify antidepressant to avoid in tamoxifen therapy due to CYP2D6 interaction. Discriminating findings: Tamoxifen use implying need for endoxifen activation; MDD requiring antidepressant. Implied: Avoid potent CYP2D6 inhibitors. Keyed C (paroxetine) fits as strong inhibitor; assumes standard metabolism knowledge. Alternatives: A (venlafaxine) - weak inhibition; B (escitalopram) - minimal; D (desvenlafaxine) - no relevant interaction; E (mirtazapine) - different mechanism, no CYP2D6 effect.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 45-year-old female with breast cancer on tamoxifen develops major depressive disorder; question asks for antidepressant contraindicated due to pharmacokinetic interaction reducing oncologic efficacy. These clues point to avoiding strong CYP2D6 inhibitors, as tamoxifen requires CYP2D6 for conversion to active endoxifen. Main logical issue(s): None; stem provides sufficient details for discrimination, with options allowing clear selection of paroxetine as the only strong inhibitor among choices. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., NCCN, ASCO) warning against strong CYP2D6 inhibitors like paroxetine with tamoxifen due to reduced endoxifen levels and potential recurrence risk. Venlafaxine, escitalopram, desvenlafaxine, and mirtazapine have minimal to no CYP2D6 inhibition. The item's logic is sound, reflecting standard pharmacotherapy knowledge without inaccuracies or outdated info. Minimal fix: None needed, as item is already unambiguous and accurate. Best-answer defensibility: Clinical problem restated - Identify antidepressant to avoid in tamoxifen therapy due to CYP2D6 interaction. Discriminating findings: Tamoxifen use implying need for endoxifen activation; MDD requiring antidepressant. Implied: Avoid potent CYP2D6 inhibitors. Keyed C (paroxetine) fits as strong inhibitor; assumes standard metabolism knowledge. Alternatives: A (venlafaxine) - weak inhibition; B (escitalopram) - minimal; D (desvenlafaxine) - no relevant interaction; E (mirtazapine) - different mechanism, no CYP2D6 effect.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-006", "question": "A patient with schizophrenia is started on clozapine. Three weeks later, he presents with fever, tachycardia, and eosinophilia. A diagnosis of clozapine-induced myocarditis is suspected and confirmed. After recovery, the psychiatric team considers a rechallenge due to treatment resistance. Under current expert consensus guidelines, which medication should be co-administered during the rechallenge to reduce the risk of recurrence?", "options": ["Lithium", "Propranolol", "Prednisone", "Lisinopril", "Metoprolol"], "answer": "D", "answer_index": 3, "explanation": "While clozapine rechallenge after myocarditis is high-risk and generally discouraged, when deemed necessary, protocols often utilize an ACE inhibitor (like lisinopril) or an ARB prophylactically. This is based on the hypothesis that the renin-angiotensin-aldosterone system plays a role in the inflammatory/fibrotic pathogenesis of the myocarditis.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's schizophrenia with treatment resistance necessitating clozapine rechallenge after confirmed myocarditis (fever, tachycardia, eosinophilia), and the query specifies co-administration per current expert consensus guidelines to reduce recurrence risk. These clues point to prophylactic use of an ACE inhibitor like lisinopril, as it targets the hypothesized role of the renin-angiotensin-aldosterone system in the inflammatory pathogenesis. Alternatives are inferior: Lithium (A) is for mood stabilization, not myocarditis prevention; Propranolol (B) and Metoprolol (E) are beta-blockers without specific evidence for this scenario; Prednisone (C) is a corticosteroid that might suppress inflammation but lacks guideline support for prophylactic use in clozapine rechallenge. Main logical issue(s): None; the stem provides sufficient details for discriminating a single best option without contradictions or underspecification. Main medical accuracy issue(s): The keyed answer aligns with some expert protocols and case series (e.g., Australian guidelines suggesting ACE inhibitors or ARBs for rechallenge), though rechallenge remains high-risk and not universally endorsed; the RAAS hypothesis is plausible but not definitively proven, representing emerging rather than fully established consensus. Minimal fix: None required, as the item is unambiguous and reasonably accurate within the constraints of current literature.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the patient's schizophrenia with treatment resistance necessitating clozapine rechallenge after confirmed myocarditis (fever, tachycardia, eosinophilia), and the query specifies co-administration per current expert consensus guidelines to reduce recurrence risk. These clues point to prophylactic use of an ACE inhibitor like lisinopril, as it targets the hypothesized role of the renin-angiotensin-aldosterone system in the inflammatory pathogenesis. Alternatives are inferior: Lithium (A) is for mood stabilization, not myocarditis prevention; Propranolol (B) and Metoprolol (E) are beta-blockers without specific evidence for this scenario; Prednisone (C) is a corticosteroid that might suppress inflammation but lacks guideline support for prophylactic use in clozapine rechallenge. Main logical issue(s): None; the stem provides sufficient details for discriminating a single best option without contradictions or underspecification. Main medical accuracy issue(s): The keyed answer aligns with some expert protocols and case series (e.g., Australian guidelines suggesting ACE inhibitors or ARBs for rechallenge), though rechallenge remains high-risk and not universally endorsed; the RAAS hypothesis is plausible but not definitively proven, representing emerging rather than fully established consensus. Minimal fix: None required, as the item is unambiguous and reasonably accurate within the constraints of current literature.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-007", "question": "A 22-year-old male presents with hypersomnia, hyperphagia, and hypersexuality occurring in distinct episodes lasting two weeks, separated by months of normal behavior. During episodes, he exhibits derealization. Which of the following pharmacologic agents has the strongest evidence for preventing future episodes of this syndrome?", "options": ["Modafinil", "Lithium", "Methylphenidate", "Fluoxetine", "Lorazepam"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation is classic for Kleine-Levin Syndrome (KLS). While symptomatic treatment involves stimulants, Lithium is the mood stabilizer with the most reported efficacy in reducing the frequency and intensity of the cycling episodes, although evidence is limited to case series and small studies.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include episodic hypersomnia, hyperphagia, hypersexuality lasting two weeks with intervening normal periods, and derealization, classic for Kleine-Levin Syndrome (KLS). These discriminate toward prophylactic treatment rather than symptomatic management. The question asks for the agent with strongest evidence for preventing episodes, pointing to Lithium based on case series and small studies showing reduced frequency/intensity. Alternatives are inferior: Modafinil and Methylphenidate are stimulants for symptomatic hypersomnia relief during episodes, not prevention; Fluoxetine (SSRI) lacks KLS-specific prophylactic evidence; Lorazepam (benzodiazepine) is for acute anxiety, not cycling prevention. No main logical issues; stem is coherent, supports unique best answer without contradictions or underspecification. Main medical accuracy issues: Evidence for Lithium is limited to observational data (no RCTs), but aligns with current consensus in neurology/psychiatry guidelines for KLS management; other options correctly portrayed as non-prophylactic. Minimal fix: None needed, as item is unambiguous and accurate; optionally add 'based on available evidence' to stem for nuance on limited data.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include episodic hypersomnia, hyperphagia, hypersexuality lasting two weeks with intervening normal periods, and derealization, classic for Kleine-Levin Syndrome (KLS). These discriminate toward prophylactic treatment rather than symptomatic management. The question asks for the agent with strongest evidence for preventing episodes, pointing to Lithium based on case series and small studies showing reduced frequency/intensity. Alternatives are inferior: Modafinil and Methylphenidate are stimulants for symptomatic hypersomnia relief during episodes, not prevention; Fluoxetine (SSRI) lacks KLS-specific prophylactic evidence; Lorazepam (benzodiazepine) is for acute anxiety, not cycling prevention. No main logical issues; stem is coherent, supports unique best answer without contradictions or underspecification. Main medical accuracy issues: Evidence for Lithium is limited to observational data (no RCTs), but aligns with current consensus in neurology/psychiatry guidelines for KLS management; other options correctly portrayed as non-prophylactic. Minimal fix: None needed, as item is unambiguous and accurate; optionally add 'based on available evidence' to stem for nuance on limited data.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-008", "question": "A 60-year-old female undergoes a laparoscopic cholecystectomy for symptomatic cholelithiasis. Final pathology reveals an incidental gallbladder adenocarcinoma invading the perimuscular connective tissue (T1b) without extension into the liver. The cystic duct margin is negative. What is the appropriate next step in management?", "options": ["Observation only", "Adjuvant chemotherapy with Gemcitabine/Cisplatin", "Radiation therapy to the gallbladder fossa", "Resection of liver segments IVb and V with portal lymphadenectomy", "Endoscopic Retrograde Cholangiopancreatography (ERCP) with stenting"], "answer": "D", "answer_index": 3, "explanation": "For T1a gallbladder cancer (invading lamina propria), simple cholecystectomy is curative. However, for T1b (invading muscle layer) and greater, there is a significant risk of lymph node metastasis and recurrence. The standard of care is radical cholecystectomy, which includes resection of the liver bed (segments IVb and V) and a portal lymphadenectomy.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues that drive (or fail to drive) a unique best answer: Incidental gallbladder adenocarcinoma invading perimuscular connective tissue (labeled T1b), no liver extension, negative cystic duct margin; question asks for next management step post-laparoscopic cholecystectomy.\\nMain logical issue(s), if any (tied to the label definitions): Contradiction - the described pathology (invasion of perimuscular connective tissue) corresponds to T2 staging per AJCC guidelines, but is incorrectly labeled as T1b (which is invasion of muscular layer), rendering the vignette internally inconsistent with established medical knowledge and making the item incoherent for determining a unique best answer based on accurate staging.\\nMain medical accuracy issue(s), if any: Major inaccuracy in staging; perimuscular connective tissue invasion is T2, not T1b. The rationale correctly describes T1b as muscle layer invasion but stem mismatches. For true T1b, radical resection (D) is often recommended but controversial, with observation (A) acceptable per NCCN in some cases; for T2, D is more definitively standard. This misleads learners on staging and management nuances.\\nMinimal fix: Revise stem to 'invading the perimuscular connective tissue (T2)' to align with AJCC staging and ensure unambiguous support for keyed answer D.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues that drive (or fail to drive) a unique best answer: Incidental gallbladder adenocarcinoma invading perimuscular connective tissue (labeled T1b), no liver extension, negative cystic duct margin; question asks for next management step post-laparoscopic cholecystectomy.\nMain logical issue(s), if any (tied to the label definitions): Contradiction - the described pathology (invasion of perimuscular connective tissue) corresponds to T2 staging per AJCC guidelines, but is incorrectly labeled as T1b (which is invasion of muscular layer), rendering the vignette internally inconsistent with established medical knowledge and making the item incoherent for determining a unique best answer based on accurate staging.\nMain medical accuracy issue(s), if any: Major inaccuracy in staging; perimuscular connective tissue invasion is T2, not T1b. The rationale correctly describes T1b as muscle layer invasion but stem mismatches. For true T1b, radical resection (D) is often recommended but controversial, with observation (A) acceptable per NCCN in some cases; for T2, D is more definitively standard. This misleads learners on staging and management nuances.\nMinimal fix: Revise stem to 'invading the perimuscular connective tissue (T2)' to align with AJCC staging and ensure unambiguous support for keyed answer D.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-009", "question": "A trauma patient presents with a Zone I retroperitoneal hematoma following a high-speed motor vehicle collision. Hemodynamics are transiently stabilized with fluids. CT scan shows the hematoma is centered around the supramesocolic midline. Intraoperatively, what is the mandated management strategy?", "options": ["Observation if the hematoma is not expanding", "Immediate exploration of the hematoma", "Angiographic embolization", "Packing and temporary closure", "REBOA placement in Zone 1"], "answer": "B", "answer_index": 1, "explanation": "Zone I retroperitoneal hematomas (central, midline) in blunt trauma are presumed to involve the aorta, vena cava, or proximal branches (celiac/SMA). Unlike Zone II (flank/kidney) or Zone III (pelvic) hematomas which may be managed non-operatively or with angioembolization if stable, a Zone I hematoma mandates surgical exploration to rule out or repair catastrophic vascular injury.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Zone I retroperitoneal hematoma in blunt trauma (high-speed MVC), centered supramesocolic midline, implying potential major vascular injury (aorta, IVC, or branches); hemodynamics transiently stabilized; intraoperative setting mandates specific strategy.\\nMain logical issue(s), if any: None; stem provides sufficient details to discriminate B as uniquely best, with no contradictions or underspecification leading to multiple defensible answers.\\nMain medical accuracy issue(s), if any: None; aligns with ATLS and trauma surgery standards where Zone I hematomas in blunt trauma require exploration due to high risk of catastrophic injury, unlike other zones amenable to non-operative management.\\nMinimal fix: None needed; item is already unambiguous and accurate.\\n\\nBest-answer defensibility: The question asks for mandated intraoperative management of a Zone I retroperitoneal hematoma in blunt trauma. Key findings: central midline location, blunt mechanism, transient stability. Most likely implies need to rule out/repair major vascular injury. Keyed answer B fits as standard mandates exploration; assumes intraoperative access. Alternatives: A incorrect for Zone I (not observable); C better for stable Zone II/III; D nonspecific damage control; E adjunct for hypotension, not hematoma-specific management.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Zone I retroperitoneal hematoma in blunt trauma (high-speed MVC), centered supramesocolic midline, implying potential major vascular injury (aorta, IVC, or branches); hemodynamics transiently stabilized; intraoperative setting mandates specific strategy.\nMain logical issue(s), if any: None; stem provides sufficient details to discriminate B as uniquely best, with no contradictions or underspecification leading to multiple defensible answers.\nMain medical accuracy issue(s), if any: None; aligns with ATLS and trauma surgery standards where Zone I hematomas in blunt trauma require exploration due to high risk of catastrophic injury, unlike other zones amenable to non-operative management.\nMinimal fix: None needed; item is already unambiguous and accurate.\n\nBest-answer defensibility: The question asks for mandated intraoperative management of a Zone I retroperitoneal hematoma in blunt trauma. Key findings: central midline location, blunt mechanism, transient stability. Most likely implies need to rule out/repair major vascular injury. Keyed answer B fits as standard mandates exploration; assumes intraoperative access. Alternatives: A incorrect for Zone I (not observable); C better for stable Zone II/III; D nonspecific damage control; E adjunct for hypotension, not hematoma-specific management.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-010", "question": "A 32-year-old female presents with acute vision loss in the left eye and retrobulbar pain. Examination reveals a central scotoma and an afferent pupillary defect. MRI shows enhancement of the left optic nerve. She is diagnosed with optic neuritis. According to the Optic Neuritis Treatment Trial (ONTT), which treatment regimen is contraindicated because it increases the rate of recurrence?", "options": ["Intravenous methylprednisolone followed by oral prednisone", "Oral prednisone alone", "Intravenous immunoglobulin (IVIG)", "Plasma exchange", "Observation alone"], "answer": "B", "answer_index": 1, "explanation": "The ONTT demonstrated that treatment with oral prednisone alone (at standard doses) not only failed to improve visual outcome compared to placebo but actually significantly increased the rate of recurrent optic neuritis. The standard of care is IV methylprednisolone (often followed by an oral taper) or observation.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the diagnosis of optic neuritis based on acute vision loss, retrobulbar pain, central scotoma, afferent pupillary defect, and MRI enhancement of the left optic nerve, with the question specifically referencing the Optic Neuritis Treatment Trial (ONTT) regarding a contraindicated treatment that increases recurrence. The stem is sufficient and consistent, allowing discrimination among options. Main logical issue(s): none; the item supports a unique best answer (B) without contradictions, underspecification, or multiple defensible choices. Option A is the recommended regimen per ONTT, speeding recovery without increasing recurrence; C and D are not standard first-line but not contraindicated by ONTT; E is a valid alternative without harm. Main medical accuracy issue(s): none; the keyed answer aligns with ONTT findings that oral prednisone alone increases recurrent optic neuritis risk, while IV methylprednisolone (often with taper) or observation are appropriate. This reflects current mainstream standards, including no improvement in long-term visual outcomes from steroids but avoidance of oral-only due to harm. Minimal fix: none needed; the item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the diagnosis of optic neuritis based on acute vision loss, retrobulbar pain, central scotoma, afferent pupillary defect, and MRI enhancement of the left optic nerve, with the question specifically referencing the Optic Neuritis Treatment Trial (ONTT) regarding a contraindicated treatment that increases recurrence. The stem is sufficient and consistent, allowing discrimination among options. Main logical issue(s): none; the item supports a unique best answer (B) without contradictions, underspecification, or multiple defensible choices. Option A is the recommended regimen per ONTT, speeding recovery without increasing recurrence; C and D are not standard first-line but not contraindicated by ONTT; E is a valid alternative without harm. Main medical accuracy issue(s): none; the keyed answer aligns with ONTT findings that oral prednisone alone increases recurrent optic neuritis risk, while IV methylprednisolone (often with taper) or observation are appropriate. This reflects current mainstream standards, including no improvement in long-term visual outcomes from steroids but avoidance of oral-only due to harm. Minimal fix: none needed; the item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-011", "question": "A neonate with Down syndrome presents with hepatosplenomegaly and a high white blood cell count consisting of blasts. A diagnosis of Transient Myeloproliferative Disorder (TMD) is made. Mutation analysis of the blasts would most likely reveal a mutation in which gene?", "options": ["JAK2", "GATA1", "RUNX1", "ETV6", "BCR-ABL"], "answer": "B", "answer_index": 1, "explanation": "TMD in Down syndrome is uniquely associated with somatic mutations in the GATA1 gene, which encodes a transcription factor required for erythroid and megakaryocytic differentiation. While TMD often resolves spontaneously, these patients are at increased risk for developing Acute Megakaryoblastic Leukemia (AMKL) later in childhood.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Neonate with Down syndrome presenting with hepatosplenomegaly and high WBC with blasts, diagnosed as Transient Myeloproliferative Disorder (TMD), drive the question toward identifying the most likely gene mutation in the blasts. These clues uniquely point to GATA1 mutations, as TMD in Down syndrome is strongly associated with somatic GATA1 mutations affecting erythroid and megakaryocytic differentiation. Main logical issue(s): None; the stem provides sufficient discriminating details (Down syndrome association, neonatal TMD diagnosis) to support a single best answer without contradictions, underspecification, or multiple defensible options. Main medical accuracy issue(s): None; the item's teaching point aligns with current hematology consensus (e.g., GATA1 mutations in ~90% of DS-TMD cases per major guidelines like WHO classification), including spontaneous resolution and AMKL risk, without inaccuracies or outdated info. Alternatives are appropriately distractors: JAK2 (myeloproliferative neoplasms), RUNX1 (familial platelet disorder/AML), ETV6 (pediatric ALL/AML translocations), BCR-ABL (CML/Ph+ ALL)—none fit DS-TMD specifically. Minimal fix: Not needed, as the item is already unambiguous and accurate; if enhancing, add 'somatic' to stem for precision on mutation type.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Neonate with Down syndrome presenting with hepatosplenomegaly and high WBC with blasts, diagnosed as Transient Myeloproliferative Disorder (TMD), drive the question toward identifying the most likely gene mutation in the blasts. These clues uniquely point to GATA1 mutations, as TMD in Down syndrome is strongly associated with somatic GATA1 mutations affecting erythroid and megakaryocytic differentiation. Main logical issue(s): None; the stem provides sufficient discriminating details (Down syndrome association, neonatal TMD diagnosis) to support a single best answer without contradictions, underspecification, or multiple defensible options. Main medical accuracy issue(s): None; the item's teaching point aligns with current hematology consensus (e.g., GATA1 mutations in ~90% of DS-TMD cases per major guidelines like WHO classification), including spontaneous resolution and AMKL risk, without inaccuracies or outdated info. Alternatives are appropriately distractors: JAK2 (myeloproliferative neoplasms), RUNX1 (familial platelet disorder/AML), ETV6 (pediatric ALL/AML translocations), BCR-ABL (CML/Ph+ ALL)—none fit DS-TMD specifically. Minimal fix: Not needed, as the item is already unambiguous and accurate; if enhancing, add 'somatic' to stem for precision on mutation type.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-012", "question": "A 2-year-old boy presents with eczema, thrombocytopenia, and recurrent pyogenic infections. He has small platelets on peripheral smear. Genetic testing reveals a mutation in the WAS gene. Which of the following malignancies is this patient at the highest risk of developing?", "options": ["Non-Hodgkin Lymphoma", "Acute Myeloid Leukemia", "Neuroblastoma", "Hepatoblastoma", "Osteosarcoma"], "answer": "A", "answer_index": 0, "explanation": "Wiskott-Aldrich Syndrome (WAS) is an X-linked disorder characterized by the triad of eczema, immunodeficiency, and thrombocytopenia with small platelets. Due to defective T-cell function and immune surveillance, these patients have a significantly elevated risk of lymphoreticular malignancies, particularly Non-Hodgkin Lymphoma (often EBV-positive).", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the classic triad of eczema, thrombocytopenia with small platelets, and recurrent pyogenic infections, confirmed by WAS gene mutation, pointing to Wiskott-Aldrich Syndrome (WAS). This syndrome is associated with defective immune surveillance, leading to high risk of lymphoreticular malignancies, specifically Non-Hodgkin Lymphoma (NHL) as the most common. Main logical issue(s): None; the stem provides sufficient discriminating details to identify NHL as the unique best answer without contradictions or underspecification, and alternatives like AML, neuroblastoma, hepatoblastoma, or osteosarcoma lack strong associations with WAS. Main medical accuracy issue(s): None; the item's teaching point aligns with current standards, as WAS patients have a well-established elevated risk of NHL (often EBV-related) due to T-cell and immune dysregulation, consistent with major guidelines and board-level knowledge. Minimal fix: None required; the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the classic triad of eczema, thrombocytopenia with small platelets, and recurrent pyogenic infections, confirmed by WAS gene mutation, pointing to Wiskott-Aldrich Syndrome (WAS). This syndrome is associated with defective immune surveillance, leading to high risk of lymphoreticular malignancies, specifically Non-Hodgkin Lymphoma (NHL) as the most common. Main logical issue(s): None; the stem provides sufficient discriminating details to identify NHL as the unique best answer without contradictions or underspecification, and alternatives like AML, neuroblastoma, hepatoblastoma, or osteosarcoma lack strong associations with WAS. Main medical accuracy issue(s): None; the item's teaching point aligns with current standards, as WAS patients have a well-established elevated risk of NHL (often EBV-related) due to T-cell and immune dysregulation, consistent with major guidelines and board-level knowledge. Minimal fix: None required; the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-013", "question": "A patient with a dual-chamber pacemaker programmed to DDD mode undergoes surgery. A magnet is placed over the device to prevent electromagnetic interference (EMI) from electrocautery. The pacemaker battery is known to be at the 'Elective Replacement Indicator' (ERI) voltage level. What is the most likely response of the pacemaker to the magnet application?", "options": ["Reversion to asynchronous DOO mode at the magnet rate", "Reversion to asynchronous VOO mode at the magnet rate", "No change in mode or rate (magnet response disabled)", "Inhibition of all pacing", "Reversion to VVI mode"], "answer": "C", "answer_index": 2, "explanation": "Normally, magnet application converts a pacemaker to an asynchronous mode (DOO/VOO) at a specific magnet rate. However, many modern pacemakers are programmed to disable the magnet response when the battery voltage drops to the Elective Replacement Indicator (ERI) or End of Life (EOL) level to conserve power or signal the battery status. Therefore, the magnet may fail to protect against EMI in this specific scenario.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: K\\nVerdict on keyed answer: Miskeyed\\nKey stem clues that drive a unique best answer: Dual-chamber pacemaker in DDD mode, magnet application during surgery to prevent EMI from electrocautery, battery at Elective Replacement Indicator (ERI) voltage level. These clues imply the pacemaker should respond to the magnet by reverting to asynchronous DOO mode at the manufacturer-specific magnet rate, which typically decreases at ERI to signal battery status, making A the unique best answer based on standard medical knowledge.\\nMain logical issue(s): The item supports a unique best answer (A), but the provided key (C) does not match it, fitting the miskeyed definition (K).\\nMain medical accuracy issue(s): The rationale and keyed answer inaccurately claim that magnet response is disabled at ERI to conserve power or signal status, contradicting mainstream standards where pacemakers revert to asynchronous pacing at an ERI-specific rate (e.g., 65 bpm in many devices). This misrepresents pacemaker behavior and could mislead learners on perioperative management.\\nMinimal fix: Change the keyed answer to A (Reversion to asynchronous DOO mode at the magnet rate), and update the rationale to reflect that the magnet rate changes at ERI but the mode reversion still occurs.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K\nVerdict on keyed answer: Miskeyed\nKey stem clues that drive a unique best answer: Dual-chamber pacemaker in DDD mode, magnet application during surgery to prevent EMI from electrocautery, battery at Elective Replacement Indicator (ERI) voltage level. These clues imply the pacemaker should respond to the magnet by reverting to asynchronous DOO mode at the manufacturer-specific magnet rate, which typically decreases at ERI to signal battery status, making A the unique best answer based on standard medical knowledge.\nMain logical issue(s): The item supports a unique best answer (A), but the provided key (C) does not match it, fitting the miskeyed definition (K).\nMain medical accuracy issue(s): The rationale and keyed answer inaccurately claim that magnet response is disabled at ERI to conserve power or signal status, contradicting mainstream standards where pacemakers revert to asynchronous pacing at an ERI-specific rate (e.g., 65 bpm in many devices). This misrepresents pacemaker behavior and could mislead learners on perioperative management.\nMinimal fix: Change the keyed answer to A (Reversion to asynchronous DOO mode at the magnet rate), and update the rationale to reflect that the magnet rate changes at ERI but the mode reversion still occurs.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-014", "question": "A patient undergoing general anesthesia with desflurane develops a rapid increase in end-tidal CO2 and tachycardia. Malignant Hyperthermia (MH) is suspected. The anesthesia machine is flushed, and dantrolene is administered. Which of the following calcium channel blockers is absolutely contraindicated in the acute management of this patient?", "options": ["Amlodipine", "Diltiazem", "Verapamil", "Nicardipine", "Nimodipine"], "answer": "C", "answer_index": 2, "explanation": "Verapamil (and diltiazem) is contraindicated in the setting of Malignant Hyperthermia, especially when dantrolene is administered. The combination of dantrolene and calcium channel blockers can lead to profound hyperkalemia and cardiovascular collapse/myocardial depression.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Anesthesiology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M. Verdict on keyed answer: Not uniquely determinable. Key stem clues: Patient on desflurane anesthesia develops rapid rise in end-tidal CO2 and tachycardia, suspect MH; machine flushed, dantrolene given; question asks for absolutely contraindicated calcium channel blocker in acute management. These clues point to avoiding agents that interact adversely with dantrolene in MH, specifically non-dihydropyridine CCBs risking hyperkalemia and CV collapse. Main logical issue(s): Both B (diltiazem) and C (verapamil) are equally defensible as contraindicated per the provided rationale and standard MH guidelines (e.g., MHAUS warnings on non-DHP CCBs with dantrolene); stem lacks discriminating details (e.g., route or specific interaction severity) to favor one over the other, allowing multiple best answers. Main medical accuracy issue(s): Core teaching point aligns with consensus that non-DHP CCBs are contraindicated in MH with dantrolene, but item overlooks nuance that both verapamil and diltiazem share this risk, potentially misleading on specificity. Minimal fix: Remove option B (Diltiazem) from choices to eliminate overlap and make C uniquely best.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M. Verdict on keyed answer: Not uniquely determinable. Key stem clues: Patient on desflurane anesthesia develops rapid rise in end-tidal CO2 and tachycardia, suspect MH; machine flushed, dantrolene given; question asks for absolutely contraindicated calcium channel blocker in acute management. These clues point to avoiding agents that interact adversely with dantrolene in MH, specifically non-dihydropyridine CCBs risking hyperkalemia and CV collapse. Main logical issue(s): Both B (diltiazem) and C (verapamil) are equally defensible as contraindicated per the provided rationale and standard MH guidelines (e.g., MHAUS warnings on non-DHP CCBs with dantrolene); stem lacks discriminating details (e.g., route or specific interaction severity) to favor one over the other, allowing multiple best answers. Main medical accuracy issue(s): Core teaching point aligns with consensus that non-DHP CCBs are contraindicated in MH with dantrolene, but item overlooks nuance that both verapamil and diltiazem share this risk, potentially misleading on specificity. Minimal fix: Remove option B (Diltiazem) from choices to eliminate overlap and make C uniquely best.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-015", "question": "A 65-year-old male presents with new-onset intention tremor and gait ataxia. MRI reveals T2 hyperintensities in the middle cerebellar peduncles (MCP sign). He has a grandson with intellectual disability. What is the molecular mechanism of the grandfather's condition?", "options": ["CGG repeat expansion > 200 causing gene methylation and silencing", "CGG repeat expansion between 55 and 200 causing mRNA toxicity", "CAG repeat expansion causing polyglutamine aggregation", "CTG repeat expansion causing RNA foci formation", "Deletion of the FMR1 gene"], "answer": "B", "answer_index": 1, "explanation": "The patient has Fragile X-associated Tremor/Ataxia Syndrome (FXTAS). This occurs in 'premutation' carriers (55-200 CGG repeats) of the FMR1 gene. Unlike Fragile X syndrome (>200 repeats, gene silencing/methylation), FXTAS is caused by a 'toxic gain-of-function' where elevated levels of FMR1 mRNA containing the repeats sequester RNA-binding proteins, leading to neurotoxicity.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 65-year-old male with intention tremor, gait ataxia, MRI MCP sign, and grandson with intellectual disability, pointing to FXTAS in a Fragile X premutation carrier. These discriminate FXTAS (premutation mRNA toxicity) from full-mutation Fragile X syndrome (gene silencing) or other repeat disorders.\\nMain logical issue(s), if any: None; stem provides sufficient clues for a single best answer without contradictions or underspecification, with options clearly differentiable.\\nMain medical accuracy issue(s), if any: None; aligns with current understanding of FMR1 disorders—premutation (55-200 CGG repeats) causes toxic gain-of-function via elevated mRNA sequestering proteins, leading to neurodegeneration in FXTAS, while >200 repeats cause methylation/silencing in Fragile X syndrome. Grandson's intellectual disability supports familial FMR1 involvement.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 65-year-old male with intention tremor, gait ataxia, MRI MCP sign, and grandson with intellectual disability, pointing to FXTAS in a Fragile X premutation carrier. These discriminate FXTAS (premutation mRNA toxicity) from full-mutation Fragile X syndrome (gene silencing) or other repeat disorders.\nMain logical issue(s), if any: None; stem provides sufficient clues for a single best answer without contradictions or underspecification, with options clearly differentiable.\nMain medical accuracy issue(s), if any: None; aligns with current understanding of FMR1 disorders—premutation (55-200 CGG repeats) causes toxic gain-of-function via elevated mRNA sequestering proteins, leading to neurodegeneration in FXTAS, while >200 repeats cause methylation/silencing in Fragile X syndrome. Grandson's intellectual disability supports familial FMR1 involvement.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-016", "question": "A patient with bipolar disorder is stable on valproate. He develops a severe infection and is prescribed meropenem. Within 48 hours, his manic symptoms recur. What is the mechanism of this drug interaction?", "options": ["Meropenem inhibits CYP2C9, increasing valproate toxicity", "Meropenem displaces valproate from albumin", "Meropenem increases the glucuronidation and renal clearance of valproate", "Meropenem acts as a direct dopamine agonist", "Meropenem induces CYP3A4, lowering valproate levels"], "answer": "C", "answer_index": 2, "explanation": "Carbapenems (like meropenem) dramatically reduce serum valproate levels, often by 50-80% within 24 hours. The mechanism involves the inhibition of acylpeptide hydrolase (which normally deconjugates valproate-glucuronide back to valproate) and increased renal clearance of the glucuronide metabolite. This interaction is rapid and can precipitate decompensation.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Patient stable on valproate for bipolar disorder develops manic recurrence within 48 hours of starting meropenem for infection, implying a drug interaction causing symptom relapse. These drive a unique best answer by pointing to reduced valproate efficacy via lowered levels, not toxicity or direct psychiatric effects. Main logical issues: None; stem is consistent, supports C as single best mechanism without contradictions or underspecification. Main medical accuracy issues: Mostly accurate per standard pharmacology; carbapenems like meropenem reduce valproate levels by inhibiting hydrolysis of valproate glucuronide (acylpeptide hydrolase), leading to increased renal clearance of the metabolite. Option C's phrasing 'increases glucuronidation' is slightly imprecise (mechanism is more about preventing deconjugation than enhancing conjugation), but aligns with net effect and is board-relevant. No major errors or outdated info; consistent with guidelines warning of this interaction. Minimal fix: Revise C to 'Meropenem inhibits hydrolysis of valproate glucuronide, increasing its renal clearance' for precision. Clinical problem: Mechanism of manic relapse due to valproate-meropenem interaction. Discriminating findings: Stability on valproate, rapid manic recurrence post-meropenem, no other changes mentioned. Likely mechanism: Decreased valproate levels via enhanced clearance. Keyed C fits: Matches known interaction without assumptions. Alternatives: A incorrect (would increase levels/toxicity, not relapse); B wrong (displacement typically minor, not rapid/severe); D unrelated to interaction; E wrong enzyme (valproate not primarily CYP3A4-metabolized).\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Patient stable on valproate for bipolar disorder develops manic recurrence within 48 hours of starting meropenem for infection, implying a drug interaction causing symptom relapse. These drive a unique best answer by pointing to reduced valproate efficacy via lowered levels, not toxicity or direct psychiatric effects. Main logical issues: None; stem is consistent, supports C as single best mechanism without contradictions or underspecification. Main medical accuracy issues: Mostly accurate per standard pharmacology; carbapenems like meropenem reduce valproate levels by inhibiting hydrolysis of valproate glucuronide (acylpeptide hydrolase), leading to increased renal clearance of the metabolite. Option C's phrasing 'increases glucuronidation' is slightly imprecise (mechanism is more about preventing deconjugation than enhancing conjugation), but aligns with net effect and is board-relevant. No major errors or outdated info; consistent with guidelines warning of this interaction. Minimal fix: Revise C to 'Meropenem inhibits hydrolysis of valproate glucuronide, increasing its renal clearance' for precision. Clinical problem: Mechanism of manic relapse due to valproate-meropenem interaction. Discriminating findings: Stability on valproate, rapid manic recurrence post-meropenem, no other changes mentioned. Likely mechanism: Decreased valproate levels via enhanced clearance. Keyed C fits: Matches known interaction without assumptions. Alternatives: A incorrect (would increase levels/toxicity, not relapse); B wrong (displacement typically minor, not rapid/severe); D unrelated to interaction; E wrong enzyme (valproate not primarily CYP3A4-metabolized).", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-017", "question": "In the forensic evaluation of a defendant's competency to stand trial (CST), which legal standard is the primary precedent in the United States?", "options": ["Durham v. United States", "Dusky v. United States", "M'Naghten Rule", "Tarasoff v. Regents of the University of California", "Ford v. Wainwright"], "answer": "B", "answer_index": 1, "explanation": "Dusky v. United States (1960) established the standard for Competency to Stand Trial. The defendant must have a 'sufficient present ability to consult with his lawyer with a reasonable degree of rational understanding' and a 'rational as well as factual understanding of the proceedings against him.' M'Naghten and Durham relate to the insanity defense (NGRI), not competency.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the focus on 'forensic evaluation of a defendant's competency to stand trial (CST)' and 'primary precedent in the United States,' pointing directly to the Dusky standard without ambiguity. The clinical problem asks for the foundational US legal case establishing CST criteria. Discriminating findings: emphasis on CST evaluation, excluding insanity defenses or other competencies. Most likely implied: Dusky v. United States, defining rational understanding of proceedings and ability to consult counsel. Keyed answer B fits precisely, requiring no assumptions. Alternatives: A (Durham) is an outdated insanity test, worse as it pertains to criminal responsibility, not competency; C (M'Naghten) is an insanity rule, incorrect for CST; D (Tarasoff) addresses duty to protect, unrelated; E (Ford) concerns execution competency, not trial. No main logical issues; stem allows clear discrimination with one best option. No main medical accuracy issues; aligns with current forensic psychiatry standards, APA guidelines, and board-relevant knowledge on CST vs. NGRI distinctions. Minimal fix: None required; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the focus on 'forensic evaluation of a defendant's competency to stand trial (CST)' and 'primary precedent in the United States,' pointing directly to the Dusky standard without ambiguity. The clinical problem asks for the foundational US legal case establishing CST criteria. Discriminating findings: emphasis on CST evaluation, excluding insanity defenses or other competencies. Most likely implied: Dusky v. United States, defining rational understanding of proceedings and ability to consult counsel. Keyed answer B fits precisely, requiring no assumptions. Alternatives: A (Durham) is an outdated insanity test, worse as it pertains to criminal responsibility, not competency; C (M'Naghten) is an insanity rule, incorrect for CST; D (Tarasoff) addresses duty to protect, unrelated; E (Ford) concerns execution competency, not trial. No main logical issues; stem allows clear discrimination with one best option. No main medical accuracy issues; aligns with current forensic psychiatry standards, APA guidelines, and board-relevant knowledge on CST vs. NGRI distinctions. Minimal fix: None required; item is unambiguous and accurate as is.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-018", "question": "A 40-year-old female presents with a 3 cm mass in the tail of the pancreas. CT imaging shows a well-circumscribed lesion with peripheral calcification. EUS-FNA is non-diagnostic but shows glycogen-rich cuboidal cells. What is the most likely diagnosis?", "options": ["Serous cystadenoma", "Mucinous cystic neoplasm", "Solid pseudopapillary neoplasm", "Pancreatic neuroendocrine tumor", "Acinar cell carcinoma"], "answer": "A", "answer_index": 0, "explanation": "Serous cystadenomas are benign lesions often found in the pancreatic tail. The classic description includes a 'honeycomb' appearance and a central scar with calcification (though peripheral calcification can occur). The key histologic feature is glycogen-rich cuboidal cells (clear cells) that stain positive for PAS. They have virtually no malignant potential.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 40-year-old female with 3 cm pancreatic tail mass, well-circumscribed on CT with peripheral calcification, and EUS-FNA showing glycogen-rich cuboidal cells. These findings—location in tail, female patient, calcification, and specific cytology—strongly support serous cystadenoma as the most likely diagnosis, a benign cystic neoplasm with characteristic glycogen-rich clear cells and low malignant potential. No main logical issues; the item is logically valid with a single defensible best answer matching the key, no contradictions, and discriminable options. No main medical accuracy issues; the keyed answer aligns with current mainstream standards, including typical presentation and histologic features per guidelines like those from the American College of Radiology and pathology consensus. The rationale accurately notes peripheral calcification as possible, though central is more classic, but this does not undermine accuracy.\\n\\nBest-answer defensibility: a) The question asks for the most likely diagnosis of a pancreatic mass based on imaging and cytology. b) Discriminating findings: positive (tail location, well-circumscribed, peripheral calcification, glycogen-rich cuboidal cells); negative (non-diagnostic FNA but specific cells noted). c) Implied diagnosis: serous cystadenoma. d) Keyed answer A fits due to matching cytology and imaging; assumes peripheral calcification is acceptable variant. e) Alternatives: B worse as mucinous epithelium lacks glycogen-rich cells; C incorrect due to solid-pseudopapillary histology (beta-catenin positive, not glycogen-rich); D lacks neuroendocrine markers; E features acinar differentiation, not cuboidal glycogen cells. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include: 40-year-old female with 3 cm pancreatic tail mass, well-circumscribed on CT with peripheral calcification, and EUS-FNA showing glycogen-rich cuboidal cells. These findings—location in tail, female patient, calcification, and specific cytology—strongly support serous cystadenoma as the most likely diagnosis, a benign cystic neoplasm with characteristic glycogen-rich clear cells and low malignant potential. No main logical issues; the item is logically valid with a single defensible best answer matching the key, no contradictions, and discriminable options. No main medical accuracy issues; the keyed answer aligns with current mainstream standards, including typical presentation and histologic features per guidelines like those from the American College of Radiology and pathology consensus. The rationale accurately notes peripheral calcification as possible, though central is more classic, but this does not undermine accuracy.\n\nBest-answer defensibility: a) The question asks for the most likely diagnosis of a pancreatic mass based on imaging and cytology. b) Discriminating findings: positive (tail location, well-circumscribed, peripheral calcification, glycogen-rich cuboidal cells); negative (non-diagnostic FNA but specific cells noted). c) Implied diagnosis: serous cystadenoma. d) Keyed answer A fits due to matching cytology and imaging; assumes peripheral calcification is acceptable variant. e) Alternatives: B worse as mucinous epithelium lacks glycogen-rich cells; C incorrect due to solid-pseudopapillary histology (beta-catenin positive, not glycogen-rich); D lacks neuroendocrine markers; E features acinar differentiation, not cuboidal glycogen cells. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-019", "question": "During a laparoscopic inguinal hernia repair (TEP), the surgeon encounters significant bleeding from an aberrant vessel crossing the superior pubic ramus, connecting the external iliac and obturator systems. This vessel is known as:", "options": ["Circle of Willis", "Corona Mortis", "Arc of Riolan", "Marginal Artery of Drummond", "Batson's Plexus"], "answer": "B", "answer_index": 1, "explanation": "The 'Corona Mortis' (Crown of Death) is a vascular connection between the obturator and external iliac systems (usually an aberrant obturator artery arising from the inferior epigastric). It crosses the superior pubic ramus in the Space of Retzius and is at high risk of injury during laparoscopic hernia repair or pelvic trauma, leading to difficult-to-control hemorrhage.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "General Surgery", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include significant bleeding from an aberrant vessel during TEP inguinal hernia repair, crossing the superior pubic ramus, and connecting the external iliac and obturator vascular systems. These details precisely describe the Corona Mortis, a known vascular anomaly at risk for hemorrhage in this surgical context. Main logical issue(s): none; the stem provides sufficient discriminating findings to identify a single best answer without contradictions, underspecification, or multiple defensible options. The alternatives are clearly incorrect based on anatomical locations: A (Circle of Willis) is cerebral; C (Arc of Riolan) and D (Marginal Artery of Drummond) are colonic anastomoses; E (Batson's Plexus) is vertebral venous. Main medical accuracy issue(s): none; the item aligns with standard anatomical knowledge and surgical risks, consistent with current guidelines on pelvic vascular anomalies in hernia repair. The rationale correctly explains the Corona Mortis as an aberrant obturator artery from the inferior epigastric, emphasizing its danger in the Space of Retzius. Minimal fix: none required, as the item is already unambiguous and accurate. The clinical problem asks for the name of this specific vascular connection, with B as the defensible choice supported by stem clues like location and bleeding risk.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include significant bleeding from an aberrant vessel during TEP inguinal hernia repair, crossing the superior pubic ramus, and connecting the external iliac and obturator vascular systems. These details precisely describe the Corona Mortis, a known vascular anomaly at risk for hemorrhage in this surgical context. Main logical issue(s): none; the stem provides sufficient discriminating findings to identify a single best answer without contradictions, underspecification, or multiple defensible options. The alternatives are clearly incorrect based on anatomical locations: A (Circle of Willis) is cerebral; C (Arc of Riolan) and D (Marginal Artery of Drummond) are colonic anastomoses; E (Batson's Plexus) is vertebral venous. Main medical accuracy issue(s): none; the item aligns with standard anatomical knowledge and surgical risks, consistent with current guidelines on pelvic vascular anomalies in hernia repair. The rationale correctly explains the Corona Mortis as an aberrant obturator artery from the inferior epigastric, emphasizing its danger in the Space of Retzius. Minimal fix: none required, as the item is already unambiguous and accurate. The clinical problem asks for the name of this specific vascular connection, with B as the defensible choice supported by stem clues like location and bleeding risk.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251223T232137723Z_gemini-3-pro-preview_seed128", "question_id": "20251223T232137723Z_gemini-3-pro-preview_seed128-020", "question": "A patient with a history of rhegmatogenous retinal detachment repair with silicone oil tamponade presents with inferior visual field loss in the same eye. Intraocular pressure is 35 mmHg. Gonioscopy reveals silicone oil emulsification in the superior angle. What is the mechanism of this glaucoma?", "options": ["Pupillary block", "Trabecular meshwork obstruction by emulsified oil droplets", "Ciliary body inflammation", "Schlemm's canal collapse", "Angle closure due to anterior displacement of the lens-iris diaphragm"], "answer": "B", "answer_index": 1, "explanation": "Silicone oil is lighter than water (aqueous humor) and floats. Over time, it can emulsify into small droplets. These droplets float into the superior angle (unlike pigment or pseudoexfoliation material which settles inferiorly) and physically obstruct the trabecular meshwork, causing secondary open-angle glaucoma. This is sometimes called 'inverse hypopyon'.", "generator_model": "gemini-3-pro-preview", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Ophthalmology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: History of rhegmatogenous retinal detachment repair with silicone oil tamponade, inferior visual field loss, elevated IOP at 35 mmHg, and gonioscopy showing silicone oil emulsification specifically in the superior angle. These clues point to emulsified oil droplets floating superiorly and obstructing the trabecular meshwork, leading to secondary open-angle glaucoma. The inferior field loss aligns with superior angle involvement affecting aqueous outflow.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (e.g., superior angle location, emulsification) to identify a single best mechanism without contradictions or underspecification. Options are distinct, allowing clear discrimination.\\nMain medical accuracy issue(s), if any: None; the item's logic aligns with established pathophysiology of silicone oil-induced glaucoma, where lighter-than-water oil emulsifies and blocks superior trabecular meshwork, consistent with current ophthalmology guidelines and board-level knowledge. No outdated or inaccurate associations present.\\nMinimal fix: No fix required as the item is already unambiguous, accurate, and supports the keyed answer uniquely.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: History of rhegmatogenous retinal detachment repair with silicone oil tamponade, inferior visual field loss, elevated IOP at 35 mmHg, and gonioscopy showing silicone oil emulsification specifically in the superior angle. These clues point to emulsified oil droplets floating superiorly and obstructing the trabecular meshwork, leading to secondary open-angle glaucoma. The inferior field loss aligns with superior angle involvement affecting aqueous outflow.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details (e.g., superior angle location, emulsification) to identify a single best mechanism without contradictions or underspecification. Options are distinct, allowing clear discrimination.\nMain medical accuracy issue(s), if any: None; the item's logic aligns with established pathophysiology of silicone oil-induced glaucoma, where lighter-than-water oil emulsifies and blocks superior trabecular meshwork, consistent with current ophthalmology guidelines and board-level knowledge. No outdated or inaccurate associations present.\nMinimal fix: No fix required as the item is already unambiguous, accurate, and supports the keyed answer uniquely.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]